SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Clinical Trials
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hu, M.
Right arrow Articles by Lan, K K G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, M.
Right arrow Articles by Lan, K K G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Applying the law of iterated logarithm to control type I error in cumulative meta-analysis of binary outcomes

Mingxiu Hu

Millennium Pharmaceuticals, 35 Landsdowne Street, Cambridge, MA 02139, USA, Mingxiu_Hu{at}yahoo.com

Joseph C Cappelleri

Pfizer Global Research & Development, New London, CT 06320, USA

K K Gordon Lan

Johnson and Johnson, New Brunswick, NJ 08933, USA

Background Cumulative meta-analysis typically involves performing an updated meta-analysis every time when new trials are added to a series of similar trials, which by definition involves multiple inspections. Neither the commonly used random effects model nor the conventional group sequential method can control the type I error for many practical situations. In our previous research, Lan et al. (Lan KKG, Hu M-X, Cappelleri JC. Applying the law of iterated logarithm to cumulative meta-analysis of a continuous endpoint. Statistica Sinica 2003; 13: 1135—45) proposed an approach based on the law of iterated logarithm (LIL) to this problem for the continuous case.

Purpose The study is an extension and generalization of our previous research to binary outcomes. Although it is based on the same LIL principle, we found the discrete case much more complex and the results from the continuous case do not apply to the binary case. The simulation study presented here is also more extensive.

Methods The LIL based method `penalizes' the Z-value of the test statistic to account for multiple tests and for the estimation of heterogeneity in treatment effects across studies. It involves an adjustment factor, which is directly related to the control of type I error and determined through extensive simulations under various conditions.

Results With an adjustment factor of 2, the LIL-based test statistics controls the overall type I error when odds ratio or relative risk is the parameter of interest. For risk difference, the adjustment factor can be reduced to 1.5. More inspections may require a larger adjustment factor, but the required adjustment factor stabilizes after 25 inspections.

Limitations It will be ideal if the adjustment factor can be obtained theoretically through a statistical model. Unfortunately, real life data are too complex and we have to solve the problem through simulation. However, for large number of inspections, the adjustment factor will have a limited effect and the type I error is controlled mainly by the LIL.

Conclusions The LIL method controls the overall type I error for a very broad range of practical situations with a binary outcome, and the LIL works properly in controlling the type I error rates as the number of inspections becomes large. Clinical Trials 2007; 4: 329—340. http://ctj.sagepub.com

Clinical Trials, Vol. 4, No. 4, 329-340 (2007)
DOI: 10.1177/1740774507081219


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Clin TrialsHome page
B. J Crowe, H. A. Xia, J. A Berlin, D. J Watson, H. Shi, S. L Lin, J. Kuebler, R. C Schriver, N. C Santanello, G. Rochester, et al.
Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team
Clinical Trials, October 1, 2009; 6(5): 430 - 440.
[Abstract] [PDF]



Advertisement